Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $6

Author: Benzinga Newsdesk | March 07, 2024 07:13am

HC Wainwright & Co. analyst Oren Livnat maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target from $5.5 to $6.

Posted In: XERS

06/28/2024 Malibu Boats, Inc. (MBUU)

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

AnaptysBio Inc (ANAB)